Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPersimmon Regulatory News (PSN)

Share Price Information for Persimmon (PSN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,355.50
Bid: 1,353.00
Ask: 1,354.50
Change: -7.50 (-0.55%)
Spread: 1.50 (0.111%)
Open: 1,369.00
High: 1,376.50
Low: 1,348.50
Prev. Close: 1,363.00
PSN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

7 Jul 2009 07:00

RNS Number : 2152V
Persimmon PLC
07 July 2009
 



TRADING UPDATE

TUESDAY 7 JULY 2009

Persimmon plc announces the following trading update ahead of its Interim Results to 30 June 2009, which will be released on Tuesday 25 August 2009.

During the six months ended 30 June 2009 we legally completed 4,006 homes with total sales revenue of c. £625 million (June 2008: £998 million). Borrowings at 30 June 2009 were lower than originally anticipated at c. £495 million (June 2008: £906 million)representing a gearing level of c. 32%. This places the business in a strong position to deliver the £450 million year end borrowings previously indicated.

At 23 April 2009 we stated that sales for the first 16 weeks of the year were ahead of our expectations. Since then sales volumes have consistently been ahead of the same period of 2008. More recently, both volume and revenues have shown increasing improvement on the comparative weeks of the previous year.

Forward sales revenue into the second half of 2009 is c. £700 million. This compares with forward sales revenue of c. £458 million at 1 January 2009 and c. £650 million at the same time last year.

We expect this improving trend to continue against the weak conditions experienced throughout the second half of 2008. House prices have continued to decline throughout the six month period with an underlying reduction of c. 4% for the Group. The rate of decline has however reduced and our recent experience is that prices are now stabilising in some locations.

Further indications of an improved housing market are evidenced by the historically low level of cancellations of c. 16% we are currently experiencing and the significant reduction in our part exchange stock to c. £17 million (June 2008: £120 million).

Whilst we continue to monitor work in progress levels very closely, we have invested where we can realise good sales and cash flow. During the first half of this year we opened 45 new developments and plan to commence work on a further c. 50 sites during the second half. Currently we have c. 390 operating sales outlets (January 2009: c. 420) (June 2008: c. 460).

Our landbank consists of c. 64,500 plots (June 2008: 76,159 plots). This represents a very healthy c. 7 years' supply at current rates of sale. Given the good geographic spread and focus on more traditional house types within our landbank, currently we do not need to acquire more land to sustain our business. However, we are identifying a small number of opportunities where we are able to agree terms to purchase new land on favourable terms. Despite this we have not experienced any noticeable increase in the availability of good quality land at attractive prices.

At the end of 2008 we carried out a prudent review of our landbank in the light of market conditions which we anticipated would lead to further market weakness. Unless there is a substantial change in current market conditions, we do not expect any requirement for further provisions. 

We are encouraged by the improvement in sales rates when compared to last year, but will remain cautious until mortgage availability improves further and employment prospects stabilise. In the meantime, we will continue to focus on cash generation and the reduction of debt levels in our business to ensure that Persimmon remains in a strong position.

Mike Farley and Mike Killoran will host a meeting with analysts at 9.00am at Merrill Lynch, 2 King Edward StreetLondon EC1A 1HQ.

Analysts wishing to participate remotely may dial 01452 569 103 followed by the conference ID 15224487.

For further information, please contact:

Persimmon plc

Mike Farley, Group Chief Executive

Mike Killoran, Group Finance Director

On 7 July 2009:  +44 (0) 207 153 1533

Thereafter: +44 (0) 1904 642 199 

M: Communications

Edward Orlebar:  +44 (0) 207 153 1523 / +44 (0) 7738 724 630

Charlotte McMullen:  +44 (0) 207 153 1549 / +44 (0) 7921 881 800

Marylene Guernier:  +44 (0) 207 153 1269 / +44 (0) 7776 303 788


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTRFMFTMMMMBFL
Date   Source Headline
19th Jun 20242:48 pmRNSDirector/PDMR Shareholding
3rd Jun 202412:33 pmRNSBlock listing Interim Review
3rd Jun 202411:08 amRNSTotal Voting Rights
23rd May 20247:00 amRNSConfirmation of CFO start date
1st May 20241:11 pmRNSTotal Voting Rights
30th Apr 20242:03 pmRNSDirectorate Change
25th Apr 20242:09 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Statement
2nd Apr 20241:49 pmRNSTotal Voting Rights
28th Mar 202412:53 pmRNSDirector/PDMR Shareholding
25th Mar 20244:47 pmRNSDirector/PDMR Shareholding
25th Mar 20242:07 pmRNSAnnual Report 2023 and Notice of AGM 2024
12th Mar 20241:38 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSFull Year Results
11th Jan 20246:00 pmRNSDechra Pharmaceuticals
10th Jan 20247:00 amRNSTrading Statement
1st Dec 20234:48 pmRNSBlock listing Interim Review
1st Dec 20234:45 pmRNSTotal Voting Rights
17th Nov 202310:25 amRNSHolding(s) in Company
8th Nov 20237:00 amRNSAppointment of Chief Financial Officer
7th Nov 20237:00 amRNSQ3 Trading Statement
3rd Nov 20231:15 pmRNSHolding(s) in Company
1st Sep 20231:15 pmRNSTotal Voting Rights
10th Aug 20237:04 amRNSHalf Year Results
27th Jul 202310:13 amRNSDirectorate Change
10th Jul 20239:27 amRNSDirector Declaration
3rd Jul 20232:46 pmRNSTotal Voting Rights
1st Jun 20234:38 pmRNSTR-1: Notification of major holdings
1st Jun 20231:07 pmRNSBlock listing Interim Review
1st Jun 202311:06 amRNSTotal Voting Rights
3rd May 20235:00 pmRNSHolding(s) in Company
3rd May 20234:12 pmRNSDirector/PDMR Shareholding
2nd May 202311:13 amRNSTotal Voting Rights
26th Apr 20234:32 pmRNSResult of AGM
26th Apr 20237:00 amRNSQ1 Trading Statement
3rd Apr 20234:01 pmRNSDirector/PDMR Shareholding
3rd Apr 20233:05 pmRNSTotal Voting Rights
27th Mar 20233:44 pmRNSDirector/PDMR Shareholding
22nd Mar 20233:00 pmRNSAnnual Report 2022 and Notice of AGM 2023
13th Mar 20231:57 pmRNSDirectorate Change
13th Mar 202312:19 pmRNSUK Government Self Remediation Contract Signed
7th Mar 20235:33 pmRNSHolding(s) in Company
7th Mar 20237:04 amRNSDirector Declaration
6th Mar 20235:02 pmRNSHolding(s) in Company
1st Mar 20237:00 amRNSFull Year Results
12th Jan 20237:00 amRNSTrading Statement
1st Dec 20225:30 pmRNSBLOCK LISTING SIX MONTHLY RETURN
1st Dec 20225:25 pmRNSVoting Rights and Capital
8th Nov 20227:00 amRNSTrading Statement
1st Nov 20221:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.